PFIZER INC

Pfizer’s latest results show a steady 18.4% operating margin and 2.1% revenue growth, driven by value‑based reimbursement wins and global supply‑chain resilience.

Pfizer’s new LITFULO vitiligo data, executive stock disclosures and Medicare pricing moves show how the pharma giant is expanding into dermatology, boosting transparency, and navigating tighter pricing rules for a competitive edge.

Pfizer’s phase‑II success with tilrekimig shows promise for atopic dermatitis, while new Medicare pricing rules and value‑based contracts reshape pharma reimbursement.

Pfizer’s September 2026 filings reveal routine insider phantom‑stock exercises, a $7 m milestone from Nurix on DACs, and a patent dispute over mRNA tech—showing steady governance, cutting‑edge research ties, and looming litigation impacts.

Pfizer’s modest share dip amid rising competition in obesity drugs highlights the need for broader pipeline diversity and regulatory agility to secure investor confidence and future growth.

Explore why Pfizer remains a stable dividend‑paying drugmaker with no new catalysts, while the pharma sector shifts toward high‑growth weight‑loss and autoimmune therapies.

Explore Pfizer’s growing oncology and immune‑therapy pipeline, from bladder‑cancer immunotherapy to lupus nephritis breakthroughs, and what it means for investors and patients.

Pfizer’s focus on autoimmune & nephrology biologics tackles rising lupus nephritis demand, balancing R&D costs, reimbursement hurdles, and patient‑access strategies.

Pfizer’s after‑hours gain mirrors cautious optimism in the pharmaceutical sector, with investors eyeing upcoming drug approvals and regulatory shifts.

Pfizer’s latest SEC filing reveals CEO ownership changes, highlights strong market gains, and shows executive mobility—offering investors a clear view of compliance, performance, and industry shifts.